INVIVO THERAPEUTICS HOLDINGS CORP.
DelistedCIK 1292519fmd_06KXF0SQHQ93T5G10Q2B0XR0CBManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2023, 56 periods
Latest annual · FY2022
Millions- Operating income
- (11)
- Net income
- (10)
- Free cash flow
- (11)
Latest quarter · Q3 FY2023
Millions- Operating income
- (3)
- Net income
- (3)
- Free cash flow
- (2)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
INVIVO THERAPEUTICS HOLDINGS CORP. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$10.7 million | -$9.9 million | 10-K 2023-03-01 · proof | |
| Net income | -$10.5 million | -$9.9 million | 10-K 2023-03-01 · proof | |
| Cash from operating activities | -$10.5 million | -$8.9 million | 10-K 2023-03-01 · proof | |
| Free cash flow | -$10.6 million | -$8.9 million | 10-K 2023-03-01 · proof | |
| Total assets | $18.8 million | $21.8 million | -13.5% | 10-K 2023-03-01 · proof |
| Total liabilities | $3.1 million | $3.7 million | -15.8% | 10-K 2023-03-01 · proof |
| Cash and cash equivalents | $16.4 million | $19 million | -14.1% | 10-K 2023-03-01 · proof |
- What was INVIVO THERAPEUTICS HOLDINGS CORP.'s operating income in fiscal 2022?
- INVIVO THERAPEUTICS HOLDINGS CORP. reported operating income of -$10.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$9.9 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was INVIVO THERAPEUTICS HOLDINGS CORP.'s net income in fiscal 2022?
- INVIVO THERAPEUTICS HOLDINGS CORP. reported net income of -$10.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$9.9 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was INVIVO THERAPEUTICS HOLDINGS CORP.'s cash from operating activities in fiscal 2022?
- INVIVO THERAPEUTICS HOLDINGS CORP. reported cash from operating activities of -$10.5 million for fiscal 2022 (the year ended Dec 31, 2022), against -$8.9 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What was INVIVO THERAPEUTICS HOLDINGS CORP.'s free cash flow in fiscal 2022?
- INVIVO THERAPEUTICS HOLDINGS CORP. reported free cash flow of -$10.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$8.9 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are INVIVO THERAPEUTICS HOLDINGS CORP.'s total assets?
- As of Dec 31, 2022, INVIVO THERAPEUTICS HOLDINGS CORP. reported total assets of $18.8 million, against $21.8 million a year earlier (-13.5%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are INVIVO THERAPEUTICS HOLDINGS CORP.'s total liabilities?
- As of Dec 31, 2022, INVIVO THERAPEUTICS HOLDINGS CORP. reported total liabilities of $3.1 million, against $3.7 million a year earlier (-15.8%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
- What are INVIVO THERAPEUTICS HOLDINGS CORP.'s cash and cash equivalents?
- As of Dec 31, 2022, INVIVO THERAPEUTICS HOLDINGS CORP. reported cash and cash equivalents of $16.4 million, against $19 million a year earlier (-14.1%). Source: the 10-K filed with the SEC on Mar 1, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1292519&period_type=annual&limit=5"Information only, not investment advice.